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Hereditary folate malabsorption (HFM) is a rare autosomal recessive disorder which is characterized by
impaired intestinal folate malabsorption and impaired folate transport into the central nervous system.
Mutations in the intestinal folate transporter PCFT have been reported previously in only 10 individuals
with this disorder. The purpose of the current study was to describe the clinical phenotype and determine
the molecular basis for this disorder in a family with four affected individuals. A consanguineous family
of Pakistani origin with autosomal recessive HFM was ascertained and clinically phenotyped. After
genetic linkage studies all coding exons of the PCFT gene were screened for mutations by direct sequenc-
ing.
The clinical phenotype of four affected patients is described. Direct sequencing of PCFT revealed a novel
homozygous frameshift mutation (c.194dupG) at a mononucleotide repeat in exon 1 predicted to result
in a truncated protein (p.Cys66LeufsX99). This report extends current knowledge on the phenotypic man-
ifestations of HFM and the PCFT mutation spectrum.
 2009 Elsevier Inc. All rights reserved.Introduction
Folates are a family of vitamins that contribute one-carbon
groups for the synthesis of nucleic acids and for the methylation
of DNA, histones, and other molecules [1]. Mammals are unable
to synthesize folates so that these essential nutrients must be ob-
tained from dietary sources [2]. Hence, intestinal folate absorption
is a critical element in folate homeostasis. Recently, the mecha-
nism of intestinal folate absorption was clariﬁed with the cloning
of the proton-coupled folate transporter (PCFT)1 which was shown
to be mutated in the autosomal recessive disorder, hereditary folate
malabsorption [3–5]. Since the initial reports, three additional kin-
dreds have been described with this disorder in which the PCFT gene
was mutated [6–8].ll rights reserved.
edical and Molecular Genet-
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action; EDTA, ethyldiamintet-Infants with HFM usually present in the ﬁrst few months of life
with failure to thrive, pallor, and often diarrhea. This is associated
with megaloblastic anemia and hypoimmunoglobulinemia often
resulting in severe infections. In many cases, there are also neuro-
logical deﬁcits such as developmental delay, mental retardation,
and seizures. This is related to a defect in the transport of folates
into central nervous system as manifested by very low levels of fo-
late in the cerebrospinal ﬂuid [5]. Unless diagnosed early, HFM can
be fatal or cause permanent neurological damage. However, if
treatment with parenteral folate or high doses of oral folate is
started early in infancy, the signs and symptoms of this disease
can resolve completely and children can develop normally.
Here we report on the clinical course of four siblings with a mild
form of HFM and demonstrate a mutation in the PCFT gene that re-
sults in the complete loss of the PCFT protein.
Methods
Subjects
A consanguineous family of Pakistani origin with four children
affected with HFM was ascertained and recruited for molecular ge-
netic analysis. Ethnically matched laboratory control samples were
analysed to evaluate the signiﬁcance of novel sequence variants.
326 E. Meyer et al. /Molecular Genetics and Metabolism 99 (2010) 325–328Participants gave informed consent; the study was approved by
South Birmingham Local Research Ethics Committee and was per-
formed in accordance with the Declaration of Helsinki.
DNA extraction
Genomic DNA was extracted from peripheral lymphocytes by
standard techniques.
Genetic linkage analysis
Prior to PFCT gene sequencing we conﬁrmed linkage with two
microsatellite markers, D17S2196 at 17.21 Mb and D17S1863 at
25.95 Mb that ﬂank the PCFT gene (located at 23.75–23.76 Mb)
on chromosome 17 (further details on request).
Mutational analysis
Mutational analysis of PCFT was carried out by direct sequenc-
ing. The genomic DNA sequence of this gene was taken from
Ensembl (http://www.ensembl.org/index.html) and primer pairs
for the translated exons ﬂanking exon–intron boundaries were de-
signed using primer3 software (http://fokker.wi.mit.edu/primer3/
input.htm). Ampliﬁcation was performed according to standard
protocols with BioMix™ Red (Bioline Ltd., London, UK). For ampli-
ﬁcation of difﬁcult fragments such as GC rich sequences either 10%
DMSO or GC rich solution of FastStart Taq DNA Polymerase (Roche
Diagnostics Ltd., Burgess Hill, UK) was added to get PCR product.
PCR conditions were an initial denaturation step at 95 C for
5 min followed 35 cycles 30 s denaturation at 95 C, 1 min anneal-
ing at 57–61.5 C (depending on fragment) and 1 min extension at
72 C with a ﬁnal extension at 72 C for 5 min. The PCR products
puriﬁed with MicroCLEAN (Web Scientiﬁc, Crewe, UK) were di-
rectly sequenced by Big Dye Terminator Cycle Sequencing System
(Applied Biosystem) and cleaned up using the EDTAmethod of pre-
cipitation. Sequencing reactions were run on an ABI PRISM 3730
DNA Analyzer (Applied Biosystem) and were analyzed using Chro-
mas software (http://www.technelysium.com.au/chromas.html).
Results
Clinical ﬁndings
Eight children were born to healthy consanguineous parents
(ﬁrst cousins) of Pakistani origin (Fig. 1). There was no family his-
tory of recurrent infection, haematological or neurological disor-
ders. All children were born following a normal pregnancy and
birth, and had an uneventful early neonatal course. Three children
(II:1, II:3 and II:7) were healthy individuals with no evidence of
haematological or neurological disease.Fig. 1. Pedigree and haplotype analysis of family with folate malabsorption. The analysi
locus as an identical homozygous haplotype is observed in all four affected individuals. F
individuals.Child II:2 died at 3 months of age secondary to bronchopneumo-
nia associated with severe anemia. On post-mortem examination,
bone marrow histology revealed megaloblastic cellular changes. A
provisional diagnosis of thalassaemia major was made (thalassae-
mia A carrier status was detected in both parents), although genetic
conﬁrmation of disease status was not undertaken.
Their fourth child (II:4), a male infant, presented at 3 months of
age with pallor and feeding difﬁculties (weight 10th centile). Gen-
eral physical examination was normal and no dysmorphic features
were evident. On haematological investigation he was found to be
anemic (8.3 g/dl, normal range: 13.0–18.0 g/dl) and subsequent
bone marrow examination conﬁrmed a severe megaloblastic pic-
ture. Further biochemical investigations showed a markedly low
folate level (serum folate: 0.58 ng/ml, normal range: 2.4–12.0 ng/
ml; red cell folate: 104 ng/ml, normal range: 160–800 ng/ml), sug-
gestive of a disorder of folate deﬁciency. Twice weekly injections of
folinic acid (3 mg i.m.) were instigated and serum folate levels nor-
malised within three weeks of starting therapy. At age three years,
CSF investigation revealed a low folate (2.7 ng/ml, normal mean:
24 ng/ml). In early childhood, he made normal neurodevelopmen-
tal progress and there were no abnormalities on neurological
examination. However from 8 years of age, there were concerns
regarding some anti-social behavioural traits. At school, mild
learning difﬁculties associated with a reduced attention span and
problems with concentration were also reported. Formal cognitive
assessment revealed that he was functioning at a level 2.5–3 years
below the expected norm. At the age of 19 years he developed
symptoms of myalgia and muscle fatigue. Nerve conduction stud-
ies and electromyelogram were normal.
The ﬁfth child, (II:5) a male infant, also presented with feeding
and breathing difﬁculties at age 2 months. His clinical presentation
and disease course was very similar to his older brother.
In light of the family history, close monitoring of subsequent
children was undertaken from birth. In patient II:6 and II:8, the
red cell folate was normal at birth, and thus folinic acid treatment
was initially deferred. However, both children presented in early
infancy with vomiting, feeding difﬁculties and shortness of breath.
In II:6, further clinical examination and cardiorespiratory investi-
gation at presentation revealed a bronchopneumonia and fulmin-
ant heart failure.
Like their older brothers, both infants developed a megaloblas-
tic anemia, and were also treated with folinic acid, following diag-
nosis of a low serum and red cell folate. Although there were
concerns regarding cognitive and motor difﬁculties on develop-
mental assessment of II:6 (age 4.5 years), these improved signiﬁ-
cantly during childhood. She proceeded to mainstream secondary
school and there were no ongoing major concerns regarding school
performance. Patient II:8 showed normal neurodevelopmentals of two microsatellite markers of each side of the PCFT gene shows linkage to this
urthermore the unaffected siblings do not share the same genotype as the affected
Fig. 2. PCFTmutation analysis. (A) Duplication of a G in exon 1 (c.194dupG; p.Cys66LeufsX99). Top panel: sequence chromatogram of a control sample with wild-type allele,
Middle panel: sequence chromatogram of the mother with the heterozygous PCFT mutation (c.194dupG). Bottom panel: sequence chromatogram of an affected individual
with the homozygous PCFT mutation (c.194dupG). (B) C>T transition at nucleotide 340 in exon 2. Top panel: sequence chromatogram of a control sample with wild-type
allele. Middle panel: sequence chromatogram of the mother with the heterozygous PCFT variant. Bottom panel: sequence chromatogram of an affected individual with the
homozygous PCFT variant.
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neither II:6 or II:8 had behavioural difﬁculties.
The patients are now age 25 (II:4), 23 (II:5), 19 (II:6) and 15
(II:8) years old. They all continue on twice weekly folinic acid
treatment (3 mg i.m.) and remain asymptomatic (no major recur-
rent infections or neurological sequelae).
Molecular genetic analysis
Molecular genetic investigation was undertaken using a posi-
tional-candidate gene approach. Thus genetic linkage studies with
ﬂanking markers (D17S2196 and D17S1863) were consistent with
linkage to the PCFT gene (maximum LOD score of 2.68 at h = 0.0 at
D17S1863; Fig. 1) and direct sequencing of the PCFT gene was then
undertaken. A novel homozygous frameshift mutation in exon 1
(c.194dupG, NM_080669.3; Fig. 2) that was predicted (in the ab-
sence of nonsense-mediatedRNAdecay) to result in a truncatedpro-
tein (p.Cys66LeufsX99, NP_542400.2) lacking 296 amino acids from
the C-terminus was detected in all affected individuals. The muta-
tion was not detected in 364 ethnically matched control chromo-
somes and showed appropriate disease segregation within the
family (themotherwas heterozygous for themutation and the unaf-
fected siblings were either heterozygous or showed wild-type se-
quence). In addition a rare missense variant was detected that
cosegregated with the frameshift mutation (c.340C>T; p.Arg114Cys).
This variant was not detected in 564 control chromosomes.
Discussion
The PCFT gene product has been implicated in folate receptor-
mediated endocytosis by serving as a route of export of folatesfrom acidiﬁed endosomes into the cytoplasm and regulates folate
transport and absorption in intestine and other human tissues at
low pH [3,9]. To date 9 different PCFT mutations (located in 4 of
the 5 exons) have been reported in 10 ethnically varied kindreds.
The novel frameshift mutation (c.194dupG; p.Cys66LeufsX99) we
identiﬁed affects the same mononucleotide tract (consisting of 7
guanines) as a previously reported frameshift mutation that is pre-
dicted to result in a different truncated protein, (c.194delG;
p.Gly65AlafsX25) [4]. This is consistent with the known hypermu-
tability of such sequence tracts. Previously c.194delG was shown
to be associated with complete lack of protein expression [4].
Although information on PCFT mutation spectrum is, as yet, re-
stricted we note that in addition to the two mutations at the exon
1 mononucleotide repeat, two mutations at the same arginine res-
idue have been reported (p.Arg113Ser and p.Arg113Cys) (Table 1)
indicating that this residue plays an important role in folate trans-
port function [4,6]. However, three previously reported missense
mutations, p.Arg113Cys, p.Arg113Ser and p.Arg376Trp occur at
hypermutable CpG dinucleotides [4,6]. All six missense mutations
affected residues that were located within, or in the direct vicinity,
of the predicted twelve transmembrane domains.
Classically HFM presents clinically in early infancy with anemia.
However, there is considerable phenotypic variation between indi-
viduals with HFM [5]. Early clinical recognition of HFM is impor-
tant because signiﬁcant morbidity and mortality may be
prevented with prompt diagnosis and treatment. The phenotype
appears to be milder in individuals where the diagnosis is made
at an early stage in infancy. However, in the absence of a positive
family history, the diagnosis may often be delayed. Certainly in
the family we describe, it is notable that the two younger children
(in whom treatment was commenced early) had fewer neurologi-
Table 1
Known mutations in PCFT in association with HFM.
Kindred (-patient) Nucleotidechange Amino acid change Mutation type Exon Ref.
1–1/2 c.1082–1 G>A p.Tyr362_Gly389 del Splice site Intron 2 [3,8]
2 c.194delG p.Gly65AlafsX25 Frameshift 1 [4]
3 c.337 C>A p.Arg113Ser Missense 2 [4]
4 c.439 G>C p.Gly147Arg Missense 2 [4]
5 c.1274 C>G p.Pro425Arg Missense 4 [4]
6 c.954 C>G; p.Ser318Arg; Missense 2; [4]
c.1126 C>T p.Arg376Trp Missense 3
7 c.337 C>T p.Arg113Cys Missense 2 [6]
8 c.197_198 GC>AA p.Cys66X Nonsense 1 [7]
9–1/4 c.194dupG p.Cys66LeufsX99 Frameshift 1 Current study
Modiﬁed from Zhao et al. [4]; Ref. = References.
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two older siblings. Molecular genetic testing can thus facilitate
early diagnosis and treatment. In families with identiﬁed disease-
causing mutations, prenatal or early antenatal testing could predict
disease status (prior to the postnatal drop in folate or haemoglobin
levels) and thus allow early folate therapy in affected cases.
To date no genotype–phenotype correlations are apparent but
functional analysis of some missense mutations (e.g. p.Arg113Ser
[4]) has shown severe effects on transporter function similar to
the effect of truncating mutations. Nevertheless, interfamilial vari-
ations in phenotype between kindreds with similar loss of function
PCFT mutations suggest that factors other than the precise nature
of the PCFT mutation inﬂuence clinical phenotype. Hence genetic
and/or environmental modiﬁer effects may also be implicated.
Interestingly, Pcft-deﬁcient mice have greatly increased homocys-
teine levels (which are also inﬂuenced by diet and genetic variants
in other genes) that could contribute to pathophysiological mani-
festations of HMF [10]. Increased recognition of HFM and the iden-
tiﬁcation of further families and PCFT mutations will provide
opportunities to deﬁne possible genotype–phenotype correlations
and further explore the basis of the marked phenotypic variability
that is characteristic of this condition.
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